Zepbound™ (tirzepatide) is an injectable prescription medicine approved by the FDA for chronic weight management in adults with obesity or excess weight (overweight) who also have weight-related medical problems
. It is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight
. In clinical trials, Zepbound helped people lose, on average, 52 pounds, nearly rivaling the weight loss results achieved with bariatric surgery
. The main ingredient in Zepbound, tirzepatide, mimics a hormone that helps reduce food cravings
. Zepbound should be used with a reduced-calorie diet and increased physical activity
. The drug is given in six injectable doses and is expected to be available by the end of December at a list price of $1,059
. It is important for patients interested in taking Zepbound to speak to their doctor prior to starting it
. The drug's ingredients work much like semaglutide, which can be found in Wegovy and Ozempic
